Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nasolacrimal drainage system implants for drug therapy

A technology of implants and therapeutic agents, applied in the field of implants, can solve problems such as blindness, vision loss in patients, and implants without drugs being delivered.

Active Publication Date: 2009-08-12
MATI THERAPEUTICS
View PDF8 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While this approach may provide some improvement over eye drops, some potential issues with this approach may include implantation of the implant at the desired tissue site, retention of the implant at the desired tissue site, and drug delivery in the desired tissue site. Sustained release at desired therapeutic levels over an extended period of time
For example, in the case of glaucoma treatment, missed diagnosis and premature loss of the implant can result in no drug being delivered and the patient could potentially suffer vision loss and possibly even blindness

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nasolacrimal drainage system implants for drug therapy
  • Nasolacrimal drainage system implants for drug therapy
  • Nasolacrimal drainage system implants for drug therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0079] Picture 1-1 and Figure 1-2 The anatomical structure of the eye 2 suitable for treatment with the implant according to an embodiment of the present invention is represented. The eye 2 includes the cornea 4 and the iris 6 . The sclera 8 surrounds the cornea 4 and the sclera 6 and appears white. The conjunctival layer 9 is substantially transparent and lies over the sclera 8 . The lens 5 is located in the eye. The retina 7 is located near the back of the eye 2 and is generally sensitive to light. The retina 7 includes the fovea 7F which provides high visual acuity and color vision. The cornea 4 and the lens 5 refract light to form an image on the fovea 7F and the retina 7 . The optical power of the cornea 4 and lens 5 facilitates image formation on the fovea 7F and retina 7 . The relative positions of the cornea 4, lens 5 and fovea 7F are also important for image quality. For example, eye 2 may be myopic if eye 2 grows from the axis of cornea 4 to retina 7F. Furt...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Cross sectionaaaaaaaaaa
Login to View More

Abstract

Implant devices, systems and methods for insertion into a punctum of a patient optionally comprises a drug core and a sheath body disposed over the drug core. The drug core includes a therapeutic agent deliverable into the eye, and the sheath defines at least one exposed surface of the drug core. The exposed surface(s) of the drug core may contact a tear or tear film fluid and release the therapeutic agent at therapeutic levels over a sustained period when the implant is implanted for use. The implant may include a retention element to retain the drug core and sheath body near the punctum, optionally comprising a shape memory alloy that can resiliently expand. An occlusive element may be attached to the retention element to at least partially occlude tear flow through the canalicular lumen.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS [0002] This application claims the benefit of US Provisional Application No. 60 / 787,775, filed March 31, 2006, and US Provisional Application No. 60 / 871,864, filed December 26, 2006, under 35 USC 119(e), all of which are The disclosure is incorporated herein by reference. technical field [0003] The present application relates to implants for use in or around a nasolacrimal drainage system, and in particular provides lacrimal canaliculus implants, lacrimal sac implants, lacrimal plugs, and lacrimal plugs with drug delivery capabilities. Background technique [0004] In the field of ocular drug delivery, patients and physicians face various challenges. Specifically, the reproducibility of treatment (multiple injections per day, multiple eye drop regimens per day), associated costs, and lack of patient compliance can significantly impact the possible treatment outcomes, leading to vision loss, many times Can cause blindness. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61F2/02
CPCA61K31/5575A61F2250/0067A61F9/00772A61K9/0051A61K47/34A61F9/0017A61F9/0026
Inventor 小尤金·德朱昂斯蒂芬·博伊德卡里·赖希艾伦·拉帕茨基汉森·S·吉福德马克·迪姆
Owner MATI THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com